(BIOT) Biotage - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000454746
BIOT: Drug discovery, Analytical testing, Water testing, Organic synthesis, Chromatography, Purification, Automation
Biotage AB (publ) is a global leader in providing innovative solutions and products for drug discovery and development, analytical testing, and water and environmental testing. The company specializes in organic and peptide synthesis solutions, including flash chromatography, evaporation, and purification systems. Its product portfolio also encompasses sample preparation solutions for clinical, bioanalytical, forensic, and environmental applications, as well as biomolecule purification solutions for antibodies, plasmids, AAV, and tagged proteins. Biotage serves a diverse range of industries, including pharmaceuticals, biotechnology, diagnostics, food safety, and environmental protection, operating across the Americas, Asia-Pacific, Europe, the Middle East, and Africa.
From a technical perspective, Biotage ABs stock (ST:BIOT) is currently trading at 141.20 SEK, above its 20-day SMA of 97.65 and 50-day SMA of 107.27 but below its 200-day SMA of 154.42, indicating potential resistance at higher levels. The Average True Range (ATR) of 5.48 suggests moderate volatility. On the fundamental side, the company has a market cap of 11,302.96M SEK, with a P/E ratio of 44.26 and a P/S ratio of 5.76, reflecting its valuation relative to earnings and sales.
3-Month Forecast: Based on the technical and fundamental data, Biotage ABs stock is expected to face resistance near the 200-day SMA of 154.42, with potential pullbacks to the 50-day SMA of 107.27. The ATR of 5.48 suggests price fluctuations of approximately 5-6% per month. Fundamentally, the high P/E ratio of 44.26 indicates investor confidence in future growth, but the stock may remain sensitive to earnings reports and industry developments.Additional Sources for BIOT Stock
BIOT Stock Overview
| Market Cap in USD | 1,170m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
BIOT Stock Ratings
| Growth Rating | -12.2 |
| Fundamental | 48.4 |
| Dividend Rating | 44.1 |
| Rel. Strength | -13 |
| Analysts | - |
| Fair Price Momentum | 125.95 SEK |
| Fair Price DCF | 66.99 SEK |
BIOT Dividends
| Dividend Yield 12m | 1.09% |
| Yield on Cost 5y | 1.52% |
| Annual Growth 5y | 1.63% |
| Payout Consistency | 83.9% |
BIOT Growth Ratios
| Growth Correlation 3m | -61.8% |
| Growth Correlation 12m | -75.8% |
| Growth Correlation 5y | -16.7% |
| CAGR 5y | 5.31% |
| CAGR/Max DD 5y | 0.08 |
| Sharpe Ratio 12m | -0.15 |
| Alpha | -18.35 |
| Beta | 0.540 |
| Volatility | 53.96% |
| Current Volume | 1577.1k |
| Average Volume 20d | 155.4k |
As of April 26, 2025, the stock is trading at SEK 140.60 with a total of 1,577,129 shares traded.
Over the past week, the price has changed by +0.89%, over one month by +40.85%, over three months by +6.08% and over the past year by -12.78%.
Partly, yes. Based on ValueRay Fundamental Analyses, Biotage (ST:BIOT) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 48.39 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BIOT as of April 2025 is 125.95. This means that BIOT is currently overvalued and has a potential downside of -10.42%.
Biotage has no consensus analysts rating.
According to ValueRays Forecast Model, BIOT Biotage will be worth about 138.6 in April 2026. The stock is currently trading at 140.60. This means that the stock has a potential downside of -1.46%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 143 | 1.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 138.6 | -1.5% |